Bivalirudin not superior to heparin in STEMI patients undergoing PCI: Circulation
Sweden: A recent study showed no benefit of Bivalirudin versus heparin in patients with STEMI undergoing primary percutaneous coronary intervention (PCI) with radial access and currently recommended treatments. The rate of the composite of all-cause death, myocardial infarction (MI), or major bleeding was not lower in those who received bivalirudin compared with heparin. The results of the study were published in the journal Circulation: Cardiovascular Interventions.
Previously, in the VALIDATE-SWEDEHEART randomized clinical trial (Bivalirudin Versus Heparin in STEMI and NSTEMI Patients on Modern Antiplatelet Therapy–Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies Registry), bivalirudin was not found to be superior to unfractionated heparin in patients with MI treated with PCI and no planned use of GPI (glycoprotein IIb/IIIa inhibitors) in contemporary clinical practice of radial access and potent P2Y12-inhibitors.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.